BMGF

British diagnostics developer Mologic announced Monday that it plans to transform from a for-profit company into a social enterprise through an acquisition worth at least $41 million. The Soros Economic Development Fund is leading the takeover with support from the Gates Foundation, according to Mologic’s press release.

Under a new name—Global Access Health—the firm aims to expand affordable access to medical technology in LMICs, including tests for diseases such as bilharzia, Covid-…

The state of the fight: 

Gavi inked a 550-million-dose supply deal with China’s CNBG and Sinovac.
  Bharat Biotech applied for WHO Emergency Use Listing of its inactivated vaccine.
  Cuba authorized BioFarmaCuba’s Abdala vaccine.

 

Approved or authorized vaccines

The U.S. FDA granted Priority Review to Pfizer/BioNTech’s Comirnaty vaccine in the companies’ bid for full licensure, the companies announced Friday.
 
While the press release noted a…

The Lancet Infectious Diseases published study results on Monday showing that the efficacy of the non-artemisinin-based triple-drug combination arterolane-piperaquine-mefloquine was noninferior to both arterolane-piperaquine and the artemisinin-based combination artemether-lumefantrine for treating uncomplicated P. falciparum malaria.

The study—funded by the Gates Foundation and Wellcome, among others—said the triple combination could “potentially be used to prevent or delay the…

Mentions:

The state of the hunt: 

WHO cleared Sinovac’s vaccine for emergency use.
  Gavi’s COVAX AMC funding summit exceeded its goals, securing $2.4 billion in commitments.
  India ordered 300 million doses of a yet-to-be-authorized Bio E vaccine candidate. Approved or authorized vaccines

Sinovac’s inactivated vaccine notched WHO Emergency Use Listing on Monday, leaving the shot, CoronaVac, eligible for supply through the COVAX Facility. Less-demanding storage requirements…

Seoul’s International Vaccine Institute (IVI) on Monday touted its Gates Foundation award to develop an adaptive trial design protocol for a Phase 1b/2a study of a schistosomiasis vaccine candidate.

A first-in-human safety study of SchistoShield (Sm-p80)—co-developed with Gates funding by Texas Tech and PAI Life Sciences, and using the GLA-SE adjuvant from IDRI—is slated to take place in the United States, followed by a Phase 1b safety and immunogenicity study in Burkina Faso and…

Mentions:

The Lancet Infectious Diseases published Phase 2 results on Tuesday comparing different durations and doses of benznidazole (a standard of care for Chagas disease) alone or in combination with the antifungal fosravuconazole. According to a press release from the Drugs for Neglected Diseases initiative (DNDi), which led the study, a two-week benznidazole Chagas treatment had “similar efficacy and significantly fewer adverse effects” than the current standard eight-week regimen of the…

CARB-X published compulsory guidance on Monday to ensure that new antibacterial products brought to market by its funded companies are used responsibly and made available to people in LMICs.

The Stewardship and Access Plan Development Guide—created by the Boston University-led nonprofit and its partners, including the Access to Medicine Foundation, the Gates Foundation, the Global Antibiotic Research and Development Partnership, the Global Antimicrobial Resistance Innovation Fund, and…

Adjuvant Capital announced last week a $300 million Global Health Technology Fund focused on accelerating the development of medical innovations for “historically overlooked public health challenges.”

The New York-based social impact investor noted in its press release that it has already backed 14 companies, requiring each to make products broadly accessible to people in low- and middle-income countries. Adjuvant’s “young portfolio” includes investments in companies addressing…

Evolve BioSystems announced observational study results on Tuesday showing that preterm infants fed its activated B. infantis probiotic (EVC001) had a “significantly lower level of intestinal inflammation, 62% less diaper rash, and required 62% fewer antibiotics.” Frontiers in Pediatrics published the results.

Evolve also reported last week that it has raised $55 million in Series D financing, led by food products group Cargill and investment firm Manna Tree. The California microbiome…

Novartis announced Wednesday a collaboration with the Gates Foundation to develop an accessible in vivo gene therapy for sickle cell disease (SCD) that could potentially be administered once, directly to a patient, without the need to modify the cells in a lab. The collaboration aims to provide affordable and practical gene therapy for low-resource settings, the press release said.

In other SCD news, Massachusetts-based Bluebird Bio announced Tuesday that it has temporarily suspended…